TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15887427
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg HPV 16 L1 VLP vaccine
Study: 15887427
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg HPV 16 L1 VLP vaccine
Study: 15887427
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg HPV 16 L1 VLP vaccine
Study: 15887427
Drug: 80 microg
Normalized name: Folic acid 80 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 microg HPV 16 L1 VLP vaccine
Study: 2853497
Drug: Intensified non‐medicamentous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified non‐medicamentous basic therapy (fat‐modified diet and endurance training)
Study: 2853497
Drug: Clofibric acid
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibric acid (1.6 g)
Study: 29276166
Drug: Accelerated oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated oxytocin titration (AOT) - initial dose 4 mU/min with increments of 4 mU/min
Study: 29276166
Drug: Standard gradual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard gradual oxytocin titration (GOT) - initial dose 2 mU/min with increments of 2 mU/min
Study: 20801085
Drug: Ciclosporin A
Normalized name: Ciclosporin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A (3.5-4.0 mg/kg per day)
Study: 20801085
Drug: Ciclosporin A
Normalized name: Ciclosporin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A with intermittent prednisone (0.75 mg/kg, alternating 10 days on with 10 days off)
Study: 10507567
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine tartrate 0.2%
Study: 1902417
Drug: Mitomycin or
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin or Adriamycin administered endovesically
Study: 28433498
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly 400mg (AOM 400)
Study: 22509905
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg nebulized ipratropium bromide
Study: 6132936
Drug: Bromazepam (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (18 mg/day)
Study: 6132936
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg/day)
Study: 23110368
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg NGX426
Study: 23110368
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg NGX426
Study: 15778883
Drug: 0.62 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.62 g/kg alcohol (A)
Study: 15778883
Drug: Declining BACs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Declining BACs (73 mg/100 ml)
Study: 15778883
Drug: Declining BACs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Declining BACs (64 mg/100 ml)
Study: 7537116
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 480 micrograms subcutaneously
Study: 7324741
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with 0.5% bupivacaine and epinephrine (5 micrograms/ml)
Study: 31199090
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg voxelotor
Study: 31199090
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg voxelotor
Study: 28202260
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Group A/B)
Study: 11143776
Drug: ACE inhibitor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor, ramipril
Study: 9292644
Drug: PGE2+oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE2+oxytocin infusion
Study: 3800032
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg orally every 6 h, beginning 24 h prior to bupivacaine administration
Study: 18258368
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 2400 mg/day)
Study: 14649343
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam (2 mg) added to hyperbaric bupivacaine (15 mg) and buprenorphine (0.15 mg)
Study: 14649343
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (15 mg) plus buprenorphine (0.15 mg)
Study: 10992829
Drug: Local morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local morphine (2 mg)
Study: 10992829
Drug: Systemic morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic morphine (2 mg)
Study: 1399498
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg twice a day for 2 weeks
Study: 27250349
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment 1
Study: 18924053
Drug: Telephone intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone intervention (weekly phone calls discussing physical activity)
Study: 27268572
Drug: Weekly writing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly writing practice alone
Study: 28929131
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist bromocriptine
Study: 28929131
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor availability assessed with PET-[18F]fallypride
Study: 24143890
Drug: Cognitive‐reminiscence therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐reminiscence therapy (six sessions of weekly, individual psychotherapy)
Study: 21165702
Drug: DAO capsules
Normalized name: Xymogen Histdao Capsules
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAO capsules
Study: 18438933
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training program for the musculature of the shoulder, held twice a week for 2 months.
Study: 11063952
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg orally 3 times a day)
Study: 28982550
Drug: L-carnitine (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3000 mg/d)
Study: 20606833
Drug: d‐ACEIs (enalapril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐ACEIs (enalapril, lisinopril, ramipril)
Study: 17822879
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with clonidine (15 microg/ml)
Study: 17822879
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (12.5 microg/ml)
Study: 10071455
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF)
Study: 9887063
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms twice daily for 4 weeks)
Study: 8777366
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B with 5.5% glucose and 100 mmol Na+
Study: 7173300
Drug: Nicotine chewing
Normalized name: nicotine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine chewing gum (Nicorette 4 mg)
Study: 25193991
Drug: Lucitanib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucitanib (doses from 5 to 30 mg)
Study: 21377114
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg BID
Study: 21377114
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg BID
Study: 11205195
Drug: 5-fluorouracil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil and folinic acid treatment
Study: 8939037
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about the target's role (active agent vs. passive recipient role)
Study: 1358243
Drug: Alfuzosin 1
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 1 mg
Study: 1358243
Drug: Alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 2.5 mg
Study: 2650730
Drug: Alfuzosin 5
Normalized name: alfuzosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 5 mg
Study: 27739231
Drug: DW1029M (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW1029M (300 mg × 2T twice daily) with losartan (50 mg once daily)
Study: 19496782
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment (mastectomy or breast conserving surgery with level I‐II axillary clearance) followed by radiation therapy to the whole breast and standard systemic therapy.
Study: 19496782
Drug: No locoregional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No locoregional treatment, standard systemic therapy given immediately after randomization.
Study: 19496782
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment (mastectomy or breast conserving surgery)
Study: 15547162
Drug: Lower in-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower in-treatment left ventricular mass index
Study: 9113931
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mean dose 18,985 units of lipase per kg per day)
Study: 8478304
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg once daily
Study: 11417442
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg four times daily
Study: 3484503
Drug: Bacterial polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial polysaccharide immune globulin (BPIG) administered intramuscularly at a dose of 0.5-0.6 ml/kg
Study: 27399735
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi training (two 60‐min sessions each week for three months, plus 30 min self‐practice daily)
Study: 20805113
Drug: 100 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U/kg unfractionated heparin (UFH)
Study: 20805113
Drug: 140 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 U/kg unfractionated heparin (UFH) (historical control)
Study: 17072885
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus conventional therapy
Study: 13678228
Drug: Keishi-bukuryo-gan (KBG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keishi-bukuryo-gan (KBG) 12 g daily for 4 weeks
Study: 13678228
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 300 mg daily for 4 weeks
Study: 10997480
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens (CEE) daily
Study: 1391559
Drug: amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin‐clavulanic acid (32 patients)
Study: 3902679
Drug: Fructose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (1 g/kg)
Study: 3902679
Drug: Glucose (1
Normalized name: Fludeoxyglucose (18F)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (1 g/kg)
Study: 30815856
Drug: Mephedrone 150
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mephedrone 150 mg
Study: 18580334
Drug: Fixed iodine-dose
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed iodine-dose protocol (80 mL Iopamidol-370, 20 seconds injection duration)
Study: 18580334
Drug: Weight-adjusted iodine-dose
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-adjusted iodine-dose protocol (1.0 mL/kg, 15 seconds injection duration)
Study: 18580334
Drug: Weight-adjusted iodine-dose
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-adjusted iodine-dose protocol
Study: 18580334
Drug: Fixed iodine-dose
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed iodine-dose protocol
Study: 16502725
Drug: OKM/A group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKM/A group: omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 500 mg or amoxicillin 1000 mg twice a day
Study: 16502725
Drug: OBTM group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBTM group: omeprazole 20 mg twice a day, colloid bismuth subcitrate (de-nol) 120 mg four times a day, tetracycline 500 mg four times a day, metronidazole 500 mg twice or 250 mg four times a day
Study: 8748321
Drug: Mannitol (2.264
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (2.264 g)
Study: 8748321
Drug: Mannitol tablet
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol tablet
Study: 31345563
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for distal radius fracture
Study: 26691278
Drug: Metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.75% cream BID
Study: 26691278
Drug: Ivermectin 1%
Normalized name: IVERMECTIN 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 1% cream QD
Study: 19648304
Drug: Conventional palpation-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional palpation-guided injection
Study: 17309916
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion plus NAC (n=111)
Study: 2569997
Drug: Acrivastine 4
Normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acrivastine 4 mg
Study: 2569995
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (Acrivastine and Terfenadine)
Study: 31758541
Drug: Follitropin alfa
Normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin alfa 'conventional' dosing arm of the ESTHER‐1 trial
Study: 25611762
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy enhanced by MP4 support (4 sessions)
Study: 25611762
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy without MP4 support (4 sessions)
Study: 24047450
Drug: Manualized supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized supportive therapy
Study: 19761535
Drug: Intravenous supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supplementation of trace elements (Se, Mn, Zn)
Study: 15819377
Drug: Drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatments (glycaemia treatment, lipidaemia treatment, blood pressure lowering, platelet aggregation inhibitors)
Study: 15819377
Drug: Multifactorial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial treatment (open randomised trial)
Study: 9571355
Drug: Perindopril (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4-8 mg daily)
Study: 9571355
Drug: Carvedilol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25-50 mg daily)
Study: 31478415
Drug: GM‐CSF supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF supplementation (0.6 ng/mL)
Study: 11312014
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine
Study: 24741050
Drug: Baclofen (GABABR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABABR agonist)
Study: 25245814
Drug: Diazepam (positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (positive modulator at GABAARs)
Study: 21254867
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin phosphate gel applied twice daily and 0.1% adapalene gel applied once daily for 4 weeks (initial treatment) followed by either OD group (adapalene applied once daily) or TW group (adapalene applied once daily on 2 days per week) for 4 weeks (maintenance phase)
Study: 20368559
Drug: Capecitabine (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (given in two divided daily doses for 14 consecutive days of a 21-day cycle for six cycles)
Study: 11284783
Drug: Nabumetone 1
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1 g b.d. by mouth for 2 weeks
Study: 11284783
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg daily for 2 weeks
Study: 11284783
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin or NSAIDs for 2 weeks)
Study: 9261860
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg KDI-792
Study: 9261860
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg KDI-792
Study: 20622370
Drug: High-dose-rate intracavitary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into 26-35 mm
Study: 20622370
Drug: High-dose-rate intracavitary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate intracavitary radiotherapy (HDR-ICRT)
Study: 19027431
Drug: Internet-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-help cognitive-behavioral therapy (CBT)
Study: 19027431
Drug: Group-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive-behavioral therapy (CBT)
Study: 16797800
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation
Study: 12560300
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg x kg(‐1)) with propofol (2.5 mg x kg(‐1))
Study: 12560300
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg x kg(‐1)) with propofol (1.5 mg x kg(‐1))
Study: 12560300
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg x kg(‐1)) without atracurium
Study: 11164075
Drug: Pharmacia‐Upjohn 15‐mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacia‐Upjohn 15‐mg, 16‐h patch
Study: 16083710
Drug: lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 100 mg/day
Study: 27080767
Drug: entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: entecavir 0.5 mg/day
Study: 27080767
Drug: standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care (no anti-viral therapy)
Study: 20720257
Drug: Lysine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine supplementation (1 g lysine/d)
Study: 18519919
Drug: BAY 63‐2521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐2521 (0.25‐5 mg)
Study: 18519919
Drug: BAY 63‐2521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐2521 (1 mg)
Study: 18519919
Drug: BAY 63‐2521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐2521 (5 mg)
Study: 16154547
Drug: Antidepressant naive
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant naive (AN) MDD subjects
Study: 16154547
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with antidepressant exposure (AE)
Study: 8609836
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg/d for 5 days)
Study: 1576049
Drug: PGI2 5
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks
Study: 1576049
Drug: PGI2 5
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks + molsidomine 12 mg daily
Study: 1576049
Drug: Molsidomine 12
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 12 mg daily
Study: 21918216
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 756 mg Ca/d
Study: 21918216
Drug: Additional 650
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional 650 mg Ca/d from dairy or calcium carbonate supplements
Study: 9093724
Drug: FEC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 100 (epirubicin 100 mg/m2)
Study: 9093724
Drug: FEC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 50 (epirubicin 50 mg/m2)
Study: 8245325
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg once daily)
Study: 31592825
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with ≤1 mL HA filler
Study: 31592825
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with ≤50 s.U ABO, ≤2 mL HA filler, and ≤1 mL RSB
Study: 24970885
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 1200 mg/d